NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Holder | Stake |
|---|---|
| Deepak Ramanlal Joshi | 2.32% |
| HDFC Mutual Fund - HDFC Pharma and Healthcare Fund | 1.69% |
| Document | Date |
|---|---|
| Annual report FY2026 BAJAJ HEALTHCARE LIMITED - ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹61,103.14 lakhs (FY 2025-26) vs ₹54,260.24 | 2026-08-29 |
| Quarterly results · Q1 FY27 BAJAJ HEALTHCARE LIMITED – Q1 FY2026-27 RESULTS SUMMARY HEADLINE NUMBERS • Revenue from operations (Q1 FY27): Rs 16,563.17 lakhs vs Rs 14,883.63 lak | 2026-07-20 |
| Quarterly results · Q4 FY26 BAJAJ HEALTHCARE LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2025-26 Revenue from Operations: Rs. 61,103.14 lakhs (vs Rs. 54,260.24 lakhs in F | 2026-05-09 |
| Quarterly results · Q3 FY26 BAJAJ HEALTHCARE LIMITED – FINANCIAL SUMMARY Q3 & 9M Results (Period Ended 31 December 2025) --- HEADLINE NUMBERS • Q3 FY2026 Revenue from Operatio | 2026-01-19 |
| Investor presentation · Q2 FY26 BAJAJ HEALTHCARE LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Total Income FY25: Rs 562.01 Cr (vs Rs 482.10 Cr in FY24, +16.6% growth) • EBITDA FY2 | 2025-12-08 |
| Quarterly results · Q2 FY26 BAJAJ HEALTHCARE LIMITED – FINANCIAL SUMMARY As of 30 September 2025 --- HEADLINE NUMBERS • Revenue from operations (H1 2025-26): ₹29,675.12 lakhs | 2025-10-17 |
| Annual report FY2025 BAJAJ HEALTHCARE LIMITED - FY2024-25 SUMMARY HEADLINE NUMBERS • Revenue FY25: ₹54,260.00 lakhs (up 14.61% YoY from ₹47,341.79 lakhs in FY24) • Net P | 2025-09-04 |
| Quarterly results · Q1 FY26 BAJAJ HEALTHCARE LIMITED – Q1 FY2025-26 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from operations (Q1 FY26): Rs 14,883.63 lakhs, down 3.7% year-o | 2025-07-29 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.50 / share ex-date Sep 11, 2026 · record Sep 14, 2026 | 2026-09-11 |
| Dividend | ₹1 / share ex-date Sep 19, 2025 | 2025-09-19 |
| Announcement | Date |
|---|---|
| NCLT approves acquisition of Genrx Pharmaceuticals on a going-concern basis Bajaj Healthcare said the Mumbai NCLT has approved its proposed acquisition of Genrx Pharmaceuticals Pvt. Ltd., a company currently in liquidation, on a “going concern” basis. The order was | 2026-10-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bajaj Healthcare Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.